Fortress Biotech

Takeda casts doubt on the remaining approach to amyloidosis

After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.

Mustang and the bubble boy bubble

The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.

September 10, 2018

World Lung preview – small-cell showdown

When the World Congress on Lung Cancer kicks off in Toronto later this month all eyes will be on Roche’s Impower-133 study.

December 14, 2017

Ash 2017 winners and losers – Déjà vu

December 07, 2017

Ash therapy focus – the other amyloidosis gets its day in the sun

November 02, 2017

Ash 2017 preview – Blueprint and Stemline celebrate

October 26, 2017

SITC preview – All eyes on Incyte and Infinity

September 05, 2017

Cellectis death casts more doubt on CD123

July 05, 2017

Biotech floats come back with a vengeance

The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.

January 04, 2017

Pharma regulatory and clinical trial news over Christmas

September 23, 2016

Snippet roundup: Firsts for Chinese CAR companies, setbacks for J&J and Mast

Load More